Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Non-Current Liabilities (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Total Non-Current Liabilities readings, the most recent being $2.4 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 54.55% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 54.55% decrease, with the full-year FY2025 number at $2.4 million, down 54.55% from a year prior.
  • Total Non-Current Liabilities hit $2.4 million in Q4 2025 for Arcadia Biosciences, down from $3.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $26.0 million in Q2 2021 to a low of $2.4 million in Q4 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $6.0 million (2022), compared with a mean of $8.0 million.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 75.98% in 2022 and later skyrocketed 79.78% in 2023.
  • Arcadia Biosciences' Total Non-Current Liabilities stood at $10.7 million in 2021, then tumbled by 43.47% to $6.0 million in 2022, then dropped by 16.94% to $5.0 million in 2023, then rose by 5.84% to $5.3 million in 2024, then crashed by 54.55% to $2.4 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $2.4 million (Q4 2025), $3.1 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.